The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Long Circulation Red‐Blood‐Cell‐Mimetic Nanoparticles with Peptide‐Enhanced Tumor Penetration for Simultaneously Inhibiting Growth and Lung Metastasis of Breast Cancer
Abstract
Limited blood circulation and poor tumor penetration are two main obstacles hampering the clinical translation of conventional nanosized drug delivery systems (NDDS). Here, red‐blood‐cell (RBC)‐mimetic nanoparticles (NPs) with long circulation and peptide‐enhanced tumor penetration for treating metastatic breast cancer are reported. The RBC‐mimetic NPs are composed of a paclitaxel (PTX)‐loaded polymeric core and a hydrophilic RBC vesicle shell. The RBC‐mimetic NPs display dramatically elongated blood circulation with an elimination half time of 32.8 h, 5.8‐fold higher than that of the parental polymeric NPs (i.e., 5.6 h). Moreover, the experimental results demonstrate that the tumor penetration ability of the RBC‐mimetic NPs can be significantly improved by coadministrating with a tumor‐penetrating peptide iRGD. Antitumor studies using a metastatic 4T1 breast tumor model show that RBC‐mimetic NPs in combination with iRGD significantly inhibit over 90% of the tumor growth and suppress 95% of the lung metastasis, much more efficient than PTX‐loaded polymer NP alone or the combination of polymer NPs and iRGD. The results reveal the importance of both long circulation and tumor penetration of nanosized drugs for efficient cancer therapy, which can provide a new insight for NDDS design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Torchilin, V. P. (2008) · Peptide Science · doi:10.1002/bip.20989 · Cited by 283
Cited by
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer
Cao, H., Dan, Z., He, X., Zhang, Z., Yu, H., Yin, Q., & Li, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b03148 · Cited by 694
Self-citationXia, Q., Zhang, Y., Li, Z., Hou, X., & Feng, N. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.01.011 · Cited by 665
Cell membrane-derived nanomaterials for biomedical applications
Fang, R. H., Jiang, Y., Fang, J. C., & Zhang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.041 · Cited by 468
An, F.-F., & Zhang, X.-H. (2017) · Theranostics · doi:10.7150/thno.19365 · Cited by 436
Liang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435
Engineered nanomedicines with enhanced tumor penetration
Ding, J., Chen, J., Gao, L., Jiang, Z., Zhang, Y., Li, M., Xiao, Q., Lee, S. S., & Chen, X. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100800 · Cited by 420
Biointerfacing and Applications of Cell Membrane-Coated Nanoparticles
Kroll, A. V., Fang, R. H., & Zhang, L. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00569 · Cited by 379
Li, J., Zhen, X., Lyu, Y., Jiang, Y., Huang, J., & Pu, K. (2018) · ACS Nano · doi:10.1021/acsnano.8b04066 · Cited by 377
Pei, Q., Hu, X., Zheng, X., Liu, S., Li, Y., Jing, X., & Xie, Z. (2018) · ACS Nano · doi:10.1021/acsnano.7b08219 · Cited by 366
Self-citationLigand-Modified Cell Membrane Enables the Targeted Delivery of Drug Nanocrystals to Glioma
Chai, Z., Ran, D., Lu, L., Zhan, C., Ruan, H., Hu, X., Xie, C., Jiang, K., Li, J., Zhou, J., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00661 · Cited by 356
Wang, Y., Zhang, K., Qin, X., Li, T., Qiu, J., Yin, T., Huang, J., McGinty, S., Pontrelli, G., Ren, J., et al. (2019) · Advanced Science · doi:10.1002/advs.201900172 · Cited by 314
Song, Q., Yin, Y., Shang, L., Wu, T., Zhang, D., Kong, M., Zhao, Y., He, Y., Tan, S., Guo, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03186 · Cited by 254
Self-citationCell membrane coated-nanoparticles for cancer immunotherapy
Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238
Liu, Y., Zou, Y., Feng, C., Lee, A., Yin, J., Chung, R., Park, J. B., Rizos, H., Tao, W., Zheng, M., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04683 · Cited by 162
Zhang, N., Li, M., Sun, X., Jia, H., & Liu, W. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.007 · Cited by 136
Tiwari, P., Yadav, K., Shukla, R. P., Gautam, S., Marwaha, D., Sharma, M., & Mishra, P. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.016 · Cited by 88
Lee, J. Y., Vyas, C. K., Kim, G. G., Choi, P. S., Hur, M. G., Yang, S. D., Kong, Y. B., Lee, E. J., & Park, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-43969-y · Cited by 47
Metadata
- Authors
- Su, J., Sun, H., Meng, Q., Yin, Q., Tang, S., Zhang, P., Chen, Y., Zhang, Z., Yu, H., & Li, Y.
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2016-01-13
- Volume
- 26
- Issue
- 8
- Pages
- 1243-1252
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W2281299635
- Cited by
- 220
- References
- 5
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.